News Financial Reports & Markets Tissue
KP Tissue shares third quarter financial results for 2023

KP Tissue has reported the Q3 2023 financial and operational results of KPT and Kruger Products (Kruger Products). KPT currently holds a 13.1 percent interest in Kruger Products.

Highlights from the results include the following:

• Revenue was $473.4 million in Q3 2023 compared to $427.0 million in Q3 2022, an increase of $46.4 million or 10.9 percent.
• Adjusted EBITDA1 was $72.4 million in Q3 2023, compared to $30.7 million in Q3 2022, an increase of 135.7 percent.
• Net income was $12.9 million in Q3 2023 compared to a net loss of $38.8 million in Q3 2022, an increase of $51.7 million.
• Declared a quarterly dividend of $0.18 per share to be paid on January 15, 2024

“We are very pleased with our Adjusted EBITDA of $72.4 million in the third quarter of 2023, highlighted by robust sales volume in our Consumer segment and improved productivity from our network assets,” stated KP Tissue’s chief executive officer, Dino Bianco. “We also benefited from a seasonally strong quarter, lower pulp and other input costs, as well as 2022 pricing carry over. As a result, we outperformed expectations despite an uncertain economic environment.”

“Looking ahead to the fourth quarter, we are seeing some moderation in input costs but continued inflationary pressure on our SG&A as labour, marketing, and IT costs, amongst others, continue to rise. We believe volume will continue to be strong and with our previously announced pricing, our margins will be stable.”

For the fourth quarter of 2023, the company expects margins to stabilize. It will continue to reinvest in the business to drive long-term value. Accordingly, Adjusted EBITDA1 in Q4 2023 is expected to be in the $60-$65 million range.

Revenue was $473.4 million in Q3 2023 compared to $427 million in Q3 2022, an increase of $46.4 million or 10.9 percent. The increase in revenue was primarily due to higher sales volume and a favourable sales mix in the consumer segment, along with the favourable impact of selling price increases implemented across all segments and regions during 2022. Revenue was also favourably impacted by foreign exchange fluctuations on U.S. dollar sales.

Cost of sales was $386.3 million in Q3 2023 compared to $394.6 million in Q3 2022, a decrease of $8.3 million or 2.1 percent. Manufacturing costs decreased as lower pulp and other input costs, along with productivity improvements in plant operations, were only partially offset by higher sales volumes and the unfavourable impact of foreign exchange fluctuations on U.S. dollar costs. Freight costs were lower compared to Q3 2022 as supply constraints and inflation moderated, while warehousing costs increased as a result of additional logistics network costs. As a percentage of revenue, cost of sales was 81.6 percent in Q3 2023 compared to 92.4 percent in Q3 2022.

Selling, general and administrative (SG&A) expenses were $40 million in Q3 2023 compared to $30.1 million in Q3 2022, an increase of $9.9 million or 33 percent. The increase was primarily due to higher advertising spend in the quarter, higher personnel costs, higher consulting costs, lower foreign exchange gains compared to the year-ago quarter and higher related party management fees. As a percentage of revenue, SG&A expenses were 8.4 percent in Q3 2023 compared to seven percent in Q3 2022.

Adjusted EBITDA was $72.4 million in Q3 2023 compared to $30.7 million in Q3 2022, an increase of $41.7 million or 135.7 percent. The significant increase was primarily due to a combination of factors: higher sales volumes and favourable sales mix, selling price increases in 2022, lower pulp and other input costs, productivity improvements in plant operations and lower freight costs. These factors were partially offset by higher warehousing and SG&A expenses and the unfavourable impact of foreign exchange fluctuations.

Net income was $12.9 million in Q3 2023 compared to a loss of $38.8 million in Q3 2022, an increase of $51.7 million. The increase was primarily due to higher Adjusted EBITDA and lower unrealized foreign exchange losses, partially offset by higher income tax expense.

As a result of significant inflation across the supply chain and interest rate increases during construction, the capital cost of the Sherbrooke Expansion Project is now forecast to increase to $377.5 million from $351.5 million. The additional costs are being financed by investments from Kruger Products and an $8.2 million increase in the construction facility. KP Tissue’s management continues to monitor the project closely to minimize the impact of any further inflation.